Material Agreement, Private Placement (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

On June 17, 2025, MAIA Biotechnology, Inc, Inc. (the "Company") entered into inducement offer letter agreements (the "Inducement Letters") with (i) certain accredited investors (the "Pre-IPO Participating Holders") that hold outstanding warrants to purchase up to an aggregate of 61,510 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") with an exercise price of $6.00 per share (the "Pre-IPO Warrants"), originally issued to the Pre-IPO Participating Holders in 2020 and 2021; (ii) certain accredited investors (the "March 2024 Participating Holders") that hold outstanding warrants to purchase up to an aggregate of 108,931 shares of Common Stock with an exercise price of $2.55 per share (the "March 2024 Warrants"), originally issued to the March 2024 Participating Holders on March 28, 2024; (iii) certain accredited investors (the "November 2024 Participating Holders") that hold outstanding warrants to purchase up to an aggregate of 22,133 shares of Common Stock with an exercise price of $2.51 per share (the "November 2024 Warrants"), originally issued to the November 2024 Participating Holders on November 1, 2024 and (iv) certain accredited investors (the "December 2024 Participating Holders," together with the Pre-IPO Participating Holders, the March 2024 Participating Holders and the November 2024 Participating Holders, the "Participating Holders") that hold outstanding warrants to purchase up to an aggregate of 26,709 shares of Common Stock with an exercise price of $2.08 per share (the "December 2024 Warrants," together with the Pre-IPO Warrants, the March 2024 Warrants and the November 2024 Warrants, the "Warrants"), originally issued to the December 2024 Participating Holders on December 13, 2024.

Pursuant to the Inducement Letters, the Participating Investors agreed to exercise for cash the Warrants into 219,283 shares of Common Stock (the "Exercise Shares") in consideration of a reduced exercise price of $1.50 per share (the "Reduced Exercise Price").

The closing of the transactions contemplated pursuant to the Inducement Letters is expected to occur on or about June 18, 2025 (the "Closing Date"). The Company is expected to receive aggregate gross proceeds of approximately $328,925 from the exercise of the Existing Warrants by the Holders at the Reduced Exercise Price, before deducting expenses payable by the Company. The Company will issue the Exercise Shares on the Closing Date, which Exercise Shares as "restricted securities", are not registered under Securities Act of 1933, as amended (the "Securities Act') and will be issued with a restrictive legend. The Company intends to use the net proceeds for general corporate purposes.

Item 3.02 Unregistered Sales of Equity Securities

The issuance of the Exercise Shares upon exercise of the Warrants will be issued pursuant to the exemption from registration provided by Section 4(a)(2), Rule 506 and/or 3(a)(9) of the Securities Act. The Company intends to use the proceeds received from the exercise of the Warrants described under Item 1.01 above for general corporate purposes.